These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 14577428)

  • 21. Respiratory arrests in young asthmatics on salmeterol.
    Shale DJ
    Respir Med; 1994 Jan; 88(1):75-6. PubMed ID: 7913244
    [No Abstract]   [Full Text] [Related]  

  • 22. Salmeterol rash.
    Hatton MQ; Allen MB; Mellor EJ; Cooke NJ
    Lancet; 1991 May; 337(8750):1169-70. PubMed ID: 1674052
    [No Abstract]   [Full Text] [Related]  

  • 23. Beta 2-agonists in asthma.
    Lancet; 1991 Feb; 337(8736):300-2. PubMed ID: 1671136
    [No Abstract]   [Full Text] [Related]  

  • 24. Medical-device safety and the FDA.
    Schultz DG
    N Engl J Med; 2008 Jul; 359(1):88-9; author reply 89. PubMed ID: 18596278
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology.
    J Allergy Clin Immunol; 1996 Sep; 98(3):475-80. PubMed ID: 8828522
    [No Abstract]   [Full Text] [Related]  

  • 26. [Beta 2 agonists between the FDA, Cochrane and reality].
    Mihălţan F; Ulmeanu R
    Pneumologia; 2009; 58(1):4-5, 7. PubMed ID: 19507479
    [No Abstract]   [Full Text] [Related]  

  • 27. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA imposes new rules for long-acting asthma drugs. Recent studies show that long-term use of LABAs alone may make asthma symptoms worse, not better.
    Duke Med Health News; 2010 May; 16(5):7. PubMed ID: 20518134
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA's recommendations on the use of long-acting {beta}2 agonists in the management of asthma.
    Robinson CA
    Ann Pharmacother; 2010 Oct; 44(10):1651-4. PubMed ID: 20841520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excess mortality with salmeterol as single-agent therapy.
    Prescrire Int; 2003 Aug; 12(66):142. PubMed ID: 12908495
    [No Abstract]   [Full Text] [Related]  

  • 31. [Established combinations of inhaled corticoids and long-acting beta 2-symphathomimetics for long-term therapy of bronchial asthma. Position of an expert panel study].
    Buhl R; Kardos P; Magnussen H; Matthys H; Sauer R; Schauer P; Vogelmeier C; Wettengel R; Worth H; Menz G
    Pneumologie; 1999 Apr; 53(4):210-2. PubMed ID: 10409864
    [No Abstract]   [Full Text] [Related]  

  • 32. Postmarket surveillance. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-agonists and death from asthma.
    Pearce N; Crane J; Burgess C; Beasley R; Jackson R
    N Engl J Med; 1992 Jul; 327(5):355-7. PubMed ID: 1352379
    [No Abstract]   [Full Text] [Related]  

  • 34. The Safe Medical Devices Act of 1990--FDA. Notice.
    Fed Regist; 1991 Apr; 56(66):14111-3. PubMed ID: 10111151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA works to reduce preventable medical device injuries.
    Rados C
    FDA Consum; 2003; 37(4):29-33. PubMed ID: 12971346
    [No Abstract]   [Full Text] [Related]  

  • 36. The Safe Medical Devices Act.
    Williams MA
    South Hosp; 1992; 58(2):16-7. PubMed ID: 10118188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recalls. FDA, industry cooperate to protect consumers.
    Nordenberg T
    FDA Consum; 1995 Oct; 29(8):24-7. PubMed ID: 10151838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
    Malone R; LaForce C; Nimmagadda S; Schoaf L; House K; Ellsworth A; Dorinsky P
    Ann Allergy Asthma Immunol; 2005 Jul; 95(1):66-71. PubMed ID: 16095144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using long-acting beta2-agonists safely: What will be the impact of the US Food and Drug Administration's panel recommendations?
    Smart BA
    Clin Cornerstone; 2009; 9(3):40-4. PubMed ID: 19781514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.